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Ⅰ?Introduction
 The KAI1 gene was originally identified as a 
putative metastasis suppressor gene for prostate 
cancer?1?and its protein is a member of the 
transmembrane-4 superfamily ?TM4SF?2,3?. 
Additional studies have shown that decreased 
KAI1 expression could be a useful marker for 
the metastatic/invasive potential in a series of 
human tumor types, including cancers of the 
prostate?4,5?, bladder?6?, breast?7?, colon?8,9?, 
and pancreas?10,11?. In addition, other studies 
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SUMMARY
KAI1 was originally identified in prostate cancer as a metastasis suppressor gene, and 
frequent down-regulation of KAI1 expression was reported in many tumor types. The aim of 
the present study was to examine whether suppressed expression of KAI1 could contribute to 
the progression and metastasis of tongue squamous cell carcinoma ?SCC?. We analyzed mu-
tational status of the KAI1 gene, and both the mRNA and protein level in a series of tongue 
SCC ?25 pre-cancerous lesions, 41 primary tongue SCCs, and 15 metastatic lymph node tu-
mors?. We found no mutation of the KAI1 gene by PCR-SSCP analysis, however, immunohis-
tochemistry revealed high frequencies of KAI1 down-regulation not only in metastatic tumors 
?100%, 15/15? but also in primary tongue SCCs ?85%, 35/41? and pre-cancerous lesions ?44%, 
11/25?. There was a significant relationship between down-regulation of KAI1 protein expres-
sion and primary tumors with lymph node metastases ?P?0.044?. Moreover, differentially 
suppressed expression levels of KAI1 were detected through multiple steps of tumor progres-
sion ?from normal tissue to carcinoma or metastatic tumor? ?P?0.01?. Our data suggest that 
suppressed regulation of KAI1 protein expression is associated with regional lymph node me-
tastasis and that the down-regulation of KAI1 is involved in the tumor progression.
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have indicated that the KAI1 mRNA expression 
level is associated with prognosis in patients 
with lung?12-14?, breast?15?, and pancreatic 
cancers?16?. These observations indicate that 
down-regulation of KAI1 expression may be 
an important step in the progression of many 
types of human malignancies. With regard to 
SCC, a higher incidence of decreased expression 
of KAI1 protein was recently reported in 
esophageal SCCs?17,18?. In contrast, a steady 
level of KAI1 mRNA expression has been 
found to be similar in both primary and 
metastatic esophageal SCCs?19?. Thus, whether 
loss of KAI1 function could contribute to the 
pathogenesis of human SCC including oral SCC 
is inconclusive. 
 In oral SCC, our previous study revealed 
that  ne i ther methylat ion nor mutat ion 
contributes to carcinogenesis, whereas loss of 
KAI1 expression is a very common event in 
metastatic lymph node tumor?20?. However, 
prevalent primary sites of oral SCC are so 
many that the mechanisms and pathways of 
progression and metastasis are very confusing 
for precise understanding. In the present study, 
we focused on only one primary site, tongue 
that is the most prevalent site of SCC in oral 
cavity, and examined the mutation and the 
state of KAI1 expression through multi-steps of 
progression and metastasis of tongue SCC. 
Ⅱ?Materials and Methods
Tissue Samples
 Forty-one pairs of tumor and corresponding 
normal tongue mucosa specimens and 15 
metastatic lesions were obtained from 41 
unrelated Japanese patients with tongue 
SCC at the time of surgical resection at the 
Department of Oral Surgery, Chiba University 
Hospital, between 2000 and 2003. Informed 
consent was obtained from all patients and the 
patients? families. In addition, 25 pre-cancerous 
tissues, which were pathologically diagnosed as 
leukoplakia, were obtained in the same manner 
as mentioned above. The resected tissues 
were divided into two parts, one of which was 
frozen immediately after careful removal of 
the surrounding normal tissues and stored at 
?80? until use; the other was fixed in 10% 
buffered formaldehyde solution for pathologic 
diagnosis and for immunohistochemical 
staining. Histopathologic diagnosis for each 
cancerous tissue was performed according to 
the International Histological Classification of 
Tumours?21?by the Department of Pathology, 
Chiba University Hospital. The clinicopathologic 
s t ag ing  was  de t e rm ined  by  the  TNM 
classification of the International Union against 
Cancer?22?. The tumor samples were checked 
to ensure that tumor tissue was present ??80% 
of specimens?.
Immunohistochemistry
 Paraff in-embedded t issue sections ?4 
?m? from 41 paired primary tongue SCCs, 
adjacent normal tongue tissues, 15 lymph 
node metastases  and 25 pre -cancerous 
l e s i on s  ? l e ukop l ak i a s? were  u s ed  f o r 
immunohistochemical detection of KAI1. After 
deparaffinizing and hydrating, the slides were 
heated in a microwave for 15 minutes in 0.01 M 
citrate buffer ?pH 6?, and rinsed three times in 
phosphate-buffered saline ?PBS? solution. After 
quenching the endogenous peroxidase activity 
in 0.3% H2O2 for 30 minutes, the sections were 
blocked for 2 hours at room temperature with 
5% bovine serum albumin before reacting with 
mouse anti-human KAI1 monoclonal antibody, 
C33 ?kindly provided by Dr Osamu Yoshie, 
Shionogi Institute for Medical Science, Osaka, 
Japan? at a dilution of 1 : 50. The sections then 
were incubated with the primary antibody for 1 
hour at room temperature in a moist chamber. 
Upon incubation with the primary antibody of 
KAI1, they were washed three times in PBS 
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buffer and treated with ENVISION reagent 
?DAKO JAPAN Inc., Kyoto, Japan? followed 
by color development in 3, 3?-diaminobenzidine 
tetrahydrochloride ?DAKO?. The slides were 
then lightly counterstained with hematoxylin, 
dehydrated in graded ethanol, cleaned in 
xylene, and mounted. To quantitate the state 
of KAI1 protein expression, a scoring method 
was applied?9?. A mean percentage of positive 
tumor cells was determined on at least ten 
fields at 400X magnification in each section. The 
intensity of KAI1 immunoreaction was scored 
as follows: ?a? weak, 1?; ?b? moderate, 2?; and 
?c? intense, 3?. The percentage of positive cells 
and the intensity of the stain were multiplied 
to produce a KAI1 immunostaining score for 
each case. Cases with the KAI1 score ?30 were 
defined as negative. Statistical significance was 
evaluated by?2 analysis.
PCR-SSCP Analysis for the KAI1 Gene Mutation
 To screen the sequence variations of 
the KAI1 gene, PCR-SSCP analysis was 
per formed as  descr ibed prev ious ly?23?
for all tongue SCC cases examined in the 
immunohistochemical analysis. Genomic DNA 
was isolated as described previously?24?. Ten 
sets of oligonucleotide primers were used 
to amplify exons from 1 to 10 of the KAI1 
gene. The sequence of each primer and each 
PCR condition was based on those reported 
previously?2?. After the amplification, the PCR 
products were then electrophoresed under 
several different conditions; at 4?, 15?, and at 
room temperature.
RT-PCR Assay of the KAI1 Gene in Tongue SCCs
 Total RNA was isolated from randomly 
selected primary tongue SCC specimens ?12 
KAI1-positive and 4 KAI1-negative cases? and 
from paired specimens of non-cancerous oral 
tissue using an SV Total RNA Isolation System 
?Promega, Madison, WI, USA? according to 
the manufacturer?s protocol. To create first-
strand cDNA, 1.5 ?g of total RNA was used 
for RT reaction. The reaction was performed 
using a Ready-To-Go T-Primed First-Strand 
Kit ?Amersham Pharmacia Biotech, Uppsala, 
Sweden?. To obtain reproducible quantitative 
performance of the RT-PCR assay, we titrated 
the amount of starting cDNA and the number of 
amplification cycles. All subsequent assays were 
carried out using the parameters that yielded 
amplification of both KAI1 and GAPDH genes 
within a linear range. cDNA was amplified by 
PCR using primers specific for cDNA of the 
KAI1 gene ?5?-AGTCCTCCCTGCTGCTGTGTG
-3?, sense; 5?-TCAGTCAGGGTGGGCAAGAGG-3?, 
antisense?. The GAPDH gene ?5?-CATCTCTGC
CCCCTCTGCTGA-3?, sense; 5?-GGATGACCTT
GCCACAGCCT-3?, antisense? was also amplified 
as an interior control resulting in 305-bp 
product. cDNA preparations were done in the 
presence and absence of reverse transcriptase, 
the latter acting as a control for contaminating 
genomic DNA from which fragments of the 
pseudogene can be amplif ied with these 
primers. PCR reactions were performed in a 
9700 Perkin-Elmer Thermal Cycler at 94? for 
1 min, 29 cycles at 94? for 40 s, 60? for 90 s, 
72? for 90 s, followed by an extension step at 
72? for 5 min. After amplification, an aliquot of 
the PCR product was separated on a 1.5% TAE-
agarose gel and stained with ethidium bromide. 
The density of the ethidium bromide-stained 
bands was analyzed using the NIH image 
software. The results were normalized as a ratio 
of each specific mRNA signal to the GAPDH 
gene signal within the same RNA sample. 
cDNA obtained from normal oral epithelium 
was used as a positive control. Reproducibility 
was confirmed by processing all samples at least 
twice.
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Ⅲ?Results
Immunohistochemistry
 A series of 41 tongue SCC patients ?29 
males and 12 females? were examined. There 
was no significant relationship between loss 
of KAI1 gene expression and age and gender 
of the patients with tongue SCC ?Table 1?. 
The correlation between the clinicopathologic 
characteristics of the cases with tongue 
SCC and KAI1 expression is summarized in 
Table 2. A strong KAI1 immunoreaction was 
successfully detected in the cellular membrane 
of the normal tongue epithelial cells on paraffin-
embedded normal tongue tissues ?Fig. 1A?. The 
KAI1 immunostaining scores for leukoplakias, 
primary tongue SCCs, and metastatic tongue 
SCCs are from 0 to 220, from 0 to 280, and 
from 0 to 75, respectively. Among the primary 
tumors examined, 35 cases ?85%? showed 
Table 1?Correlation of KAI1 protein expression in IHC and patients? profile.
Total number 
of cases
Number of patients ?%?
P value
KAI1 ??? KAI1 ???
Age at surgery ?yrs?
?60 24 20?83? 4?17?
60 to ?70 8 7?88? 1?12? NS?
?70 9 8?89? 1?11?
Gender
Male 29 25?86? 4?14? NS?
Female 12 10?83? 2?17?
???? ?NS; not significant.
Table 2?Correlation between the expression of KAI1 protein in IHC and clinical classification.
Clinical classification
Total No. 
of cases
Number of patients ?%?
P value
KAI1 ??? KAI1 ???
T of primary tumor
T1 6 4? 67? 2?33?
NS?
T2 13 12? 92? 1? 8?
T3 6 6?100? 0? 0?
T4 16 13? 81? 3?19?
Regional lymph node metastasis
N??? 26 20? 77? 6?23?
0.044?
N??? 15 15?100? 0? 0?
Tumors in metastatic L/N 15 15?100? 0? 0?
Stage
I 5 4? 80? 1?20?
NS
II 9 9?100? 0? 0?
III 7 6? 86? 1?14?
IV 20 16? 80? 4?20?
Histopathological type   
Well differentiated 25 21? 84? 4?16?
Moderately diff. 10 9? 90? 1?10? NS
Poorly diff. 6 5? 83? 1?17?
?NS; not significant. 
? ;  There was a significant down-regulation of KAI1 protein expression between primary tumor with 
and without lymph node metastasis by ?2 analysis.
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significant down-regulation of KAI1 protein 
?Table 3; Fig. 1B, E, F?. All of metastatic tongue 
SCCs within the lymph nodes showed absent 
or reduced KAI1 immunostaining ?Table 3?. 
Moreover, almost all of the primary tongue 
SCC with regional lymph node metastasis 
showed down-regulation of KAI1 protein 
expression and a statistical significance was 
observed between the KAI1-reduced primary 
tongue SCCs with and without lymph node 
metastasis ?P?0.044; Table 2?. On the other 
hand, there was no statistically significant 
difference between KAI1 expression and other 
clinicopathologic features ?Table 2?. Twenty-
five tongue pre-cancerous lesions histologically 
diagnosed as leukoplakia were also examined 
for the state of KAI1 protein expression using 
the same immunohistochemical method. Eleven 
cases ?44%? of the leukoplakias were defined 
as KAI1-negative ?Table 3?. There was a 
significant down-regulation of KAI1 protein 
expression associated with tumor progression; 
from normal tissues to metastatic tumors ?P?
0.01?. Representative results are shown in Fig. 
1C, and 1D.
Mutation Analyses of the KAI1 Gene
 PCR-SSCP analysis to screen for the KAI1 
gene mutation was done for all subjects 
examined in immunohistochemical analysis. 
No mobility shift in SSCP patterns, however, 
was detected in either KAI1-negative or KAI1-
overexpressed cases ?data not shown?.
KAI1 Gene Expression in Tongue SCC Tissues 
Analyzed by RT-PCR Assay
 A l l  pr imary  tumors  showing down-
regulation of KAI1 protein expression ?n?35? 
by immunohistochemistry revealed significantly 
reduced mRNA expression, whereas a steady 
Fig. 1? Immunohistochemical staining of KAI1 in 
normal and cancerous tongue tissues. 
?A?  Normal tongue tissue exhibited strong KAI1 
protein expression that was limited to the cell 
membrane. Original magnification, X200.
?B?  KAI1-negative case of metastatic SCC. 
Original magnification, X400.
?C?  KAI1-positive case of leukoplakia. Note that 
strong positive immunoreaction for KAI1 
was detected on the epithelial cell membrane. 
Original magnification, X200.
?D?  KAI1-negative case of leukoplakia. Original 
magnification, X200.
?E?  Positive staining of tumor cells of the primary 
tongue SCC. Original magnification, X400.
?F?  Negative staining of tumor cells of the 
primary tongue SCC. Original magnification, 
X400. 
Table 3?Correlation between the expression of KAI1 protein in IHC and tumor progression.
KAI1
expression
Normal
tissues
Leukoplakias
Primary
tumors
Metastatic
tumors
P value
??? 0??0? 11?44? 35?85? 15?100?
?0.01?
??? 41?100? 14?56? 6?15? 0? 0?
Total No. 41??? 25? ? 41? ? 15? ?
? ;  There was a significant down-regulation of KAI1 protein expression associated with tumor 
progression ?from normal tissues to metastatic tumors?. 
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state level of the gene expression was observed 
in KAI1-positive cases ?n?6?. Typical examples 
of the RT-PCR analysis are shown in Fig. 2.
Ⅳ?Discussion
 KAI1, a novel member of the transmembrane-4 
superfamily ?TM4SF?, is located at chromosome 
11p11.2 and encodes a transmembrane protein 
of 267 amino acids?1?. KAI1 has been shown 
to suppress metastasis in a Dunning rat model 
of prostatic adenocarcinoma?1?, and the down-
regulation of KAI1 is associated with tumor 
metastasis in multiple human tumors of lung
?13?, breast?15?, pancreas?16?, bladder?6?, colon
?8,9?, and esophagus?17,18?. Recent studies have 
reported that this gene inhibits cellular invasion 
and mortality in colon cancer cell lines in vitro?25?
and overexpression of KAI1 in breast cancer cells 
resulted in suppressed experimental invasion in 
vitro and metastasis in vivo?26?.
 In the current study, we found that no 
genetic mutation of the KAI1 gene occurred 
in either primary or metastatic tongue SCCs, 
agreeing with other previous reports?5,18,27?. 
Thus, it seems that down-regulation of the 
KAI1 gene was not commonly caused by gene 
mutation. 
 To date, most studies of the KAI1 gene 
have suggested that this gene may influence 
the metastatic ability of human cancers. We 
observed down-regulation of the KAI1 protein in 
all ?100%? of metastatic oral tumors. Therefore, 
our observations for tongue SCCs agree with 
the evidence that KAI1 expression is reduced in 
the majority of metastatic tumors. On the other 
hand, we observed its down-regulation in almost 
half ?44%? of pre-cancerous lesions investigated 
?Table 3?. Therefore, we suggest that the 
marked down-regulation of KAI1 can be seen as 
a precipitous event in tongue carcinogenesis. All 
of the primary tongue SCCs that had metastatic 
lesions was found to have extensive KAI1 
down-regulation. Finally, as shown in Table 
3, the frequency of KAI1 expression loss was 
differentially increased according to the steps 
of tumor progression ?precancerous lesion, 
primary carcinoma, and metastatic tumor?. 
Our data indicate that loss of KAI1 expression 
is involved in tumor progression as well as 
metastasis.
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Fig. 2? Representative results of RT-PCR analysis.
?Absent  or  s ign i f i cant ly  reduced KAI1 
expressions in mRNA from tumor tissues are 
evident in tongue SCC patients when compared to 
each corresponding normal tissue. 
?tumors, T; corresponding normal tissues, N; 
molecular marker, M. 
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